Amphastar Pharmaceuticals
AMPH
135 hedge funds and large institutions have $591M invested in Amphastar Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 9 closing their positions.
267% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 9
66% more capital invested
Capital invested by funds: $355M → $591M (+$236M)
22% more funds holding
Funds holding: 111 → 135 (+24)
13% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 38
5.28% more ownership
Funds ownership: 51.73% → 57.01% (+5.3%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$14.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$9.65M |
| 3 |
BlackRock
New York
|
+$7.41M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
+$4.81M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.16M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$3.11M |
| 3 |
Goldman Sachs
New York
|
-$2.47M |
| 4 |
Morgan Stanley
New York
|
-$2.06M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$1.83M |
AMPH Hedge Fund Activity: Q2 2020 in Review
135 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2020, worth a combined $591M — up 66% from $355M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AMPH positions and 9 closed out — a net gain of 24 holders — while 43 added to existing stakes and 38 trimmed.
The largest buyer was Fuller & Thaler Asset Management, opening a new position worth an estimated $14.9M. The largest seller was Renaissance Technologies, cutting an estimated $4.16M.
- 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2020, up from 111 in Q1 2020.
- Funds reported $591M of Amphastar Pharmaceuticals stock for Q2 2020, up 66% quarter-over-quarter.
- 33 funds opened new Amphastar Pharmaceuticals positions in Q2 2020 and 9 closed out, a net change of +24 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2020 was Fuller & Thaler Asset Management, an estimated $14.9M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2020 was Renaissance Technologies, an estimated $4.16M sold.
Based on aggregated 13F filings for Q2 2020.